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Background: The Charcot-Leyden crystal (CLC) pro-
tein is a major autocrystallizing constituent of human
eosinophils and basophils, comprising -10% of the total
cellular protein in these granulocytes. Identification of the
distinctive hexagonal bipyramidal crystals of CLC protein
in body fluids and secretions has long been considered a
hallmark of eosinophil-associated allergic inflammation.
Although CLC protein possesses lysophospholipase activ-
ity, its role(s) in eosinophil or basophil function or associ-
ated inflammatory responses has remained speculative.
Results: The crystal structure of the CLC protein has
been determined at 1.8 A resolution using X-ray crystal-
lography. The overall structural fold of CLC protein is
highly similar to that of galectins -1 and -2, members of
an animal lectin family formerly classified as S-type or
S-Lac (soluble lactose-binding) lectins. This is the first
structure of an eosinophil protein to be determined and
the highest resolution structure so far determined for any
member of the galectin family.
Conclusions: The CLC protein structure possesses a car-
bohydrate-recognition domain comprising most, but not
all, of the carbohydrate-binding residues that are con-
served among the galectins. The protein exhibits specific
(albeit weak) carbohydrate-binding activity for simple
saccharides including N-acetyl-D-glucosamine and lac-
tose. Despite CLC protein having no significant sequence
or structural similarities to other lysophospholipases or
lipolytic enzymes, a possible lysophospholipase catalytic
triad has also been identified within the CLC structure,
making it a unique dual-function polypeptide. These
structural findings suggest a potential intracellular and/or
extracellular role(s) for the galectin-associated activities of
CLC protein in eosinophil and basophil function in aller-
gic diseases and inflammation.
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Introduction
Charcot-Leyden crystals (CLCs) were first described in
Paris in 1853 by Charcot and Robin in the post-mortem
spleen and heart blood of a leukemia patient [1]. A later
report by Leyden described them in the sputum of asth-
matics [2], ultimately resulting in their designation as
Charcot-Leyden crystals. These distinctive hexagonal,
bipyramidal crystals have classically been observed in tis-
sues and secretions from sites of eosinophil-associated
inflammatory and related allergic immune reactions in
asthma, myeloid leukaemias, allergic, parasitic and other
eosinophil-associated diseases [3,4]. Although CLCs are
considered a hallmark of the eosinophil, basophils also
form CLCs [5], and CLCs have been identified ultra-
structurally as intragranular inclusions in the large hista-
mine-containing, particle-filled granule of the human
blood basophil and basophils that participate in a variety
of inflammatory tissue reactions [6,7].
Eosinophil CLCs are formed by a small (16.5 kDa)
markedly hydrophobic polypeptide (CLC protein) [8],
comprising 142 amino acids [9,10], that exhibits
lysophospholipase (LPLase) activity (lysolecithin acyl-
hydrolase EC 3.1.1.5) [11,12]. CLC protein is indistin-
guishable from chromatographically purified human
eosinophil LPLase and both proteins crystallize to form
morphologically identical hexagonal, bipyramidal crystals
[12]. The cDNA for CLC protein directs CLC crystal-
lization and the expression of LPLase activity in tran-
siently transfected COS and CHO cells [10,11]. CLC
protein is one of the most abundant constituents of the
eosinophil [5, 8], comprising an estimated 7-10% of total
cellular protein in this granulocyte [12], an amount com-
parable with the eosinophil's content of secondary gran-
ule cationic toxins and enzymes such as the major basic
protein and eosinophil peroxidase [13].
The amino-acid sequence of CLC protein shows essen-
tially no significant similarities with available sequences
of prokaryotic or eukaryotic LPLases or other lipolytic
enzymes [9,10], including LPLases of rat [14] and bovine
[15] origin as well as a series of sulphydryl-dependent
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LPLases of mouse macrophage [16] and human myeloid
cell (HL-60) origins [17] that have been partially
sequenced. In contrast, the CLC protein shows limited
amino-acid-sequence identity to the family of animal
galectins [9,10], previously known as S-type or S-Lac
(soluble lactose-binding) lectins [18,19]. So far, eight
mammalian galectins, designated galectin-1 to -8, and
many non-mammalian galectins, have been reported.
The galectins are defined by their affinity for P-galacto-
sides and twelve highly conserved residues in their
sequence that comprise their carbohydrate-recognition
domain. Most of the conserved residues are involved
in interaction with bound carbohydrate, as shown by
X-ray crystallography of galectins -1 and -2 [20-22] and
site-directed mutagenesis [23-25]. The CLC protein
sequence contains seven out of the twelve conserved
residues and in addition shares many other residues with
the mammalian galectins [9,10]. It is most similar to
galectins -3 and -4 (25-30% overall identity) and least
similar to galectins -1 and -2 (15-20% overall identity).
In addition to these sequence similarities, CLC protein
has some functional similarities to the galectins. Like the
galectins, CLC protein is predominantly found as an
abundant cytosolic protein and lacks a secretion signal
peptide, but may under certain conditions be released
extracellularly [26-28]. Regulated non-classical secre-
tion has been demonstrated for galectins [29-32] as well
as the CLC protein [33,34]. In addition, like galectins
[35], the CLC protein is also found in the nucleus of
both eosinophils and basophils [6,11,36,37]. The bio-
logical roles of CLC protein and galectins remain
unknown, but both CLC protein and galectin-3 have
been proposed to be involved in allergic immunological
responses. Galectin-3 has been independently identified
as the IgE binding protein EBP, the laminin- and IgE-
binding macrophage surface antigen Mac-2, as well as
the carbohydrate binding proteins CBP35, L-34 and
L-29 [18, 19]. Galectin-3 is expressed in eosinophils,
neutrophils, macrophages and epithelial cells. It has been
suggested that it may mediate the interaction of IgE
with neutrophils and eosinophils [38,39] and can act to
induce a signalling response in various leukocytes
[40-42]. Intracellularly, galectin-3 has been identified as
a factor involved in pre-mRNA splicing in HeLa cell
nuclear extracts [35]. These findings suggest that CLC
protein should possess galectin-like carbohydrate-bind-
ing activities and possibly other galectin-like properties
that might be extremely pertinent to eosinophil and
basophil function in allergic inflammation, especially
taking into consideration the major cellular content and
subcellular localization of this enigmatic autocrystallizing
polypeptide. As very few prokaryotic or eukaryotic pro-
teins undergo autocrystallization intracellularly or extra-
cellularly in a physiological setting, the ability of CLC to
form hexagonal bipyramidal crystals is perhaps the most
intriguing of its physicochemical properties. Although
the physicochemical or structural properties of CLC
protein responsible for autocrystallization, and the
precise biological role that this plays, have not been
determined, the LPLase activity of CLC protein is
inactivated by crystallization [10].
In this report, we present a detailed structural analysis of
CLC protein to 1.8 A resolution. Despite minimal over-
all sequence conservation, the CLC protein structural
topology is remarkably similar to that of galectins -1 and
-2. In addition, we demonstrate functional, albeit weak,
binding of CLC protein to lactose and N-acetyl-D-
glucosamine, and identify structural differences in the
carbohydrate-recognition domain of CLC protein, rela-
tive to other galectins, that are likely to be responsible for
the low affinity for these saccharides. We also highlight
the features of a putative LPLase active site, making CLC
a unique protein with a dual functional role.
Results
The crystal structure of CLC protein was determined by
the multiple isomorphous replacement method (see the
Materials and methods section; Table 1). The experi-
mentally derived phases were used to build a model for
the CLC protein structure and refined against the data to
1.8 A resolution to a final crystallographic R value of
20.0%. In general, the electron-density map is of high
quality (Fig. 1). The entire structure is well defined and
rigid except for the C-terminal residue, the main chain
of Tyr139 and the terminal portions of the side chains
Lys23, Arg25, Lys45, Arg60, Gln74, Gln87, Lys134 and
Lys141, all of which have high temperature factors and
are disordered.
Table 1. Statistics for crystallographic structure determination.
Crystal Native p-CMBS K2PtCI 4
Internal scaling
Resolution (A) 40-1.8 45-3.4 45-3.4
Number of crystals 2 1 1
Reflections measured 75 363 14557 9526
Unique reflections 18046 3130 3074
Completeness (%) 94.4 99.1 96.6
(outermost shell) (89.2) (98.0) (93.8)
I/ol 9.1 10.0 9.1
Rsym* (%) 7.7 6.2 6.5
Derivative scaling
Resolution (A) 15-3.4 15-3.4
Mean fractional
isomorphous difference (%) 32.4 35.4
Heavy-atom refinement
Phasing powert 2.42 1.55
Number of sites 2 2
Coordinating residues Cys29,Cys57 Met44,Met103
Rcullis (%) 37.0 52.7
RKraut§ (%) 15.8 20.6
Figure of merit# 0.65 0.46
*Rsym=Shi Ill(h)-li(h) I/hlili(h), where li(h) and (h) are the ith and
the mean measurements of the intensity of reflection h. tPhasing
Power is the ratio of the rms calculated heavy-atom structure
amplitude to the rms lack of closure. tRcullis= I I FPHI obs I + F I obs I -
I FH Icc /l I FPH I obs± I F obs I, where FPH and Fp are the observed
structure factor amplitudes for the heavy-atom derivative and the native
data sets, with the sum taken over all centric reflections, and FH
is the heavy-atom structure factor. RKraut= I FPH Iob s- FPH Icalc
FH obs, with the sum taken over all acentric reflections. *The figure
of merit after phase combination is 0.60.
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Fig. 1. Stereoview of a portion of the
final 1.8 A 2 1 F I - Fc I electron-density
map for CLC protein. The map is con-
toured at 1.0acr level. (The figure was
generated using the program 0 [68].)
Fig. 2. The three-dimensional structure
of human CLC protein. (a) Orthogonal
views of CLC protein structure.
3 strands are presented in cyan, the two
small 310 helices in red and the loops in
yellow. (b) Stereoview of the Ca back-
bone of CLC protein molecule. (The dia-
grams were drawn using MOLSCRIPT
[74].)
Structure description
CLC protein is a compact molecule with approximate
monomer dimensions of 43 A x 35 A x 31 A (Fig. 2). The
topological motif consists of a 'jelly-roll', which results
from tight association between a five-stranded (F1-F5)
and a six-stranded (S1-S6a/S6b) sheet, as described
for galectins -1 and -2 [20-22]. The molecule has very
little loop structure, with the majority of residues
adopting conformation. Two short 310 helices (one
situated at the top and the other at the bottom in
Fig. 2b) connecting 13 strands F2-S3 and F5-S2, respec-
tively, form part of the decorations of the molecule. The
last residue at the C terminus is disordered and is
modelled as alanine in the refined structure. One pep-
tide bond connecting residues Val6 and Pro7 adopts
a cis conformation.
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Fig. 3. Structural details of CLC protein.
(a) Structure-based sequence alignment
of CLC protein, bovine heart galectin-1
(1 SLC) and human galectin-2 (1 HLC) as
determined using the program SHP 172].
Every tenth residue in the CLC sequence
is numbered. Residues that form the car-
bohydrate-binding site are boxed. The
dots indicate gaps inserted for optimal
alignment. In CLC protein the solvent
inaccessible residues (less than 20 A2 of
exposed surface as calculated using the
program DSSP [711) are indicated by #
and residues involved in crystal packing
contacts are marked by . Polar interac-
tions are indicated by lower case letters
and water mediated interactions <4.0 A
are highlighted in grey boxes. Sec-
ondary structural elements ( strands
F1-F5, S1-S6b) as determined by DSSP
171] are also shown. Residues which are
identical between CLC protein and
galectins are highlighted in bold letters.
(b) Diagram of hydrogen bonds involv-
ing main-chain atoms in the CLC pro-
tein structure. Squares indicate residues
in 13 strands and circles indicate residues
in 310 turns. Arrows represent hydrogen
bonds. (Figure drawn using the program
HERA [75].) (c) Stereoviews of the struc-
tural alignment of CLC protein (black)
on bovine heart galectin-1 (1SLC, red),
bovine spleen galectin-1 (1SLT, green)
and human galectin-2 (1 HLC, cyan).
The high degree of structural conserva-
tion is apparent.
A structure-based sequence alignment of CLC protein
with known galectin structures -1 and -2 (Fig. 3a) indi-
cates which CLC protein residues are either solvent inac-
cessible or involved in crystal contacts. Figure 3b
indicates the detailed hydrogen bond network between
the strands within the CLC protein molecule. The close
structural resemblance between galectins and CLC pro-
tein is shown in Figure 3c; the regions that deviate signif-
icantly are the loop regions connecting the strands. In a
structural comparison of CLC protein and galectin-1,
excluding these loops reduces the root mean square (rms)
deviation from 1.91 A to 1.19 A.
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Table 2. Structural superposition of different protein structures that possess similar topology to the CLC protein.
CLC 1SLT 1SLC 1HLC WING1 1LTE
1.91
1SLT 1.91
24/127
1.91
1SLC 1.91
24/127
2.01
1 HLC 2.01
24/128
2.60
WING1 2.51
11/112
3.54
1LTE 3.25
11/101
3.12
1 SAC 3.00
9/100
3.26
2AYH 2.88
7/121
3.54
2LTN 3.25
11/101
4.04
WING2 2.73
6/90
4.25
2PHL 4.58
4/56
4.27
1PNG 3.92
4/55
4.14
1CEL 2.97
5/88
0.50
0.50
133/133
0.74
0.74
55/128
3.35
3.01
9/113
2.71
2.92
17/124
3.18
3.18
12/115
3.10
2.85
12/121
2.88
3.11
14/127
2.90
2.90
9/112
3.87
4.35
9/63
4.68
3.26
3/57
4.32
3.24
7/91
1.03
1.03
55/128
3.05
2.45
7/112
2.81
3.11
14/123
3.16
3.20
8/93
4.55
2.89
9/92
2.96
2.81
15/128
3.14
3.97
7/113
5.46
3.92
4/57
3.09
3.00
4/78
3.15
3.18
9/118
4.46
3.30
2/81
3.28
2.97
6/119
3.32
3.26
4/95
2.76
2.91
13/117
3.26
3.12
9/121
2.90
2.90
11/111
4.44
3.53
5/58
2.89
4.31
9/79
4.11
3.44
3/100
3.62
2.45
6/157
3.27
3.47
11/134
3.14
2.55
19/56
3.29
2.92
7/121
1.53
1.45
33/145
4.60
4.88
5/77
4.53
3.30
5/81
4.27
3.93
14/145
3.37
2.97
12/142
3.15
2.76
12/172
2.92
1.56
86/178
2.84
2.71
9/130
4.29
4.94
4/80
4.73
3.83
6/81
3.21
3.08
17/167
1SAC 2AYH 2LTN WING2 2PHL 1PNG
3.41
2.71
7/134
3.39
3.36
5/97
3.70
3.57
10/151
4.52
4.01
5/77
4.17
3.56
4/169
3.53
3.75
7/92
2.96
3.29
8/128
3.32
3.28
13/129
5.01
4.18
7/77
4.96
3.69
7/71
2.76
2.82
20/181
2.83
2.83
5/94
4.96
4.22
3/70
4.55
3.27
2/67
3.04
3.10
13/127
5.87
5.25
5/72
5.36
4.16
4/81
4.45
4.53
3/89
5.00
4.20
7/110
3.66
4.51
5/84
4.49
3.62
8/100
Brookhaven Protein Data Bank accession numbering is used for each protein: bovine spleen galectin-1, 1SLT [21]; bovine heart
galectin-1, 1SLC [201; human galectin-2, 1HLC [22]; pea lectin, 2LTN [77]; coral tree lectin (EcorL), 1LTE [76]; serum amyloid P
component (SAP), 1SAC [48]; Wing 1 and Wing 2 are the lectin-like domains of the Vibrio cholerae neuraminidase [50];
P-glucanase lichenase, 2AYH [78]; cellulase, 1CEL [47]; plant seed storage protein phaseolin, 2PHL [79]; and asparagine amidase,
1 PNG [44]. First row (bold) corresponds to the overall rms distance between the proteins, the second row is the rms distance for the
part of the structure which has the lectin-like topology, and third row shows the number of identical amino-acid residues over the
number of equivalent residues between the two structures. Structural alignments were made using the SHP program [72].
Similarity to other lectin-like structures
A detailed structural comparison of CLC protein with
known 'jelly-roll' structures is shown in Table 2 and Fig-
ure 4. It is clear from such an extensive comparison that
CLC protein and galectins form part of a unique family
of soluble calcium-independent carbohydrate-binding
animal lectins and differ from cation-dependent carbo-
hydrate-binding plant lectins. The 'jelly-roll' motif in the
CLC protein structure is a common, core structural
motif found in the diverse group of lectin molecules for
which the structures are known so far. But, even if CLC
protein and galectin-1 and -2 have the same fold as the
legume lectins, they are much more similar in structure
to each other than to these lectins. Furthermore, they
show no sequence homology to the legume lectins or
any of the other proteins with the same type of fold.
More recently, several new molecules possessing the
'jelly-roll' motif have been identified. In particular, the
3D structures of four enzymes have been elucidated:
peptide-N-glycosidase F (glycosylasparaginase) [43,44],
bacterial 1,3-1,4-3-glucanase [45], endo 1,4-,3-xylanase
II [46] and cellulase cellobiohydrolase I [47]. The carbo-
hydrate-binding mode of these enzymes appears to have
similar features to that of the legume lectins, that is, the
carbohydrate molecules bind to the concave face of the
3 sheet with the loops surrounding the ligand.
Interestingly, three new proteins have been identified
which possess lectin-like domains (Table 2, Fig. 4) and
are relevant to our discussion: human serum amyloid P
component protein [48], which has lectin activity and
binds to DNA and amyloid fibrils; human C-reactive
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Fig. 4. The lectin domain in CLC pro-
tein. This domain is compared with
bovine spleen galectin-1 complexed
with N-acetyl-lactosamine [21]; human
galectin-2 complexed lactose [22]; coral
tree lectin complexed with lactose
[76]; 3-D-glucanase complexed with
3,4-epoxy-butyl-3-D-cellobioside [45];
the N-terminal domain of asparagine
amidase [44]; Human serum amyloid P
component [48] and Wing-i from Vib-
rio cholerae neuraminidase [50]. Bound
metal ions are shown as green spheres.
The N and C termini are shown as blue
and red spheres, respectively. The coor-
dinates of the lectin domains of the vari-
ous proteins have been transformed
after superposition onto CLC protein
using the program SHP [72].
protein [49], which is an acute phase reactant and has
been identified as a galactose-specific particle receptor on
liver macrophages, and lectin-like domains (Wings 1 and
2) attached to the catalytic domain in Vibrio cholerae
neuraminidase [50]. It has not yet been established
whether these wings possess any lectin activity, but it has
been suggested that they may be involved in promoting
adhesion to epithelial cells. Comparison of these domains
with CLC protein has revealed considerable similarity
with the Wing 1 domain (Table 2). Thus, these proteins
appear to possess elaborated forms of the 'jelly-roll'
motif and belong to the ConA-like lectin superfamily of
proteins, on the basis of structural classification using the
SCOP database search [51].
Environment of cysteine residues
The CLC protein molecule contains two cysteine
residues (Cys29 and Cys57). Both cysteines appear to be
active as they bind mercury atoms, and from the elec-
tron-density map it was clear that both cysteines have a
reactive sulphydryl group. Cys29 is situated at the
beginning of a small 3 10 helix connecting strands F2
and S3 and Cys57 is located at the end of strand S4. In
the crystal structure Cys29 is accessible to solvent,
whereas Cys57 is buried, and these cysteines are not
involved in disulphide bond formation (they are at a
separation of 12 A). These residues are not involved
in any strong crystal packing interactions and the
closest atom to Cys29 is OE1 of Glu46 from a
symmetry related molecule (3.9 A) and to Cys57 is Oq
of Tyr35 from the same molecule (4.0 A). These
observations from the molecular structure raise ques-
tions as to why only a single reactive sulphydryl can be
detected in the denatured protein using either
5,5'-dithiobis(2-nitrobenzoic acid) [8], p-chloromer-
curibenzoic or iodoacetic acids [12].
The carbohydrate-recognition site
On the basis of mutagenesis data for human galectin-1,
Hirabayashi and Kasai [24] have suggested that the most
conserved residues are located in the central region of
the galectin amino-acid sequence. In particular, six
hydrophilic residues are well conserved: His44, Asn46,
Arg48, Asn61, Glu71 and Arg73. These residues,
together with Trp68, form part of the carbohydrate-
recognition site in galectins. More detailed pictures of
galectin-1 complexed with biantennary saccharides [20]
and N-acetyl-lactosamine [21], and galectin-2 in com-
plex with lactose [22], have recently been obtained by X-
ray crystallography. These studies reveal highly conserved
carbohydrate-binding sites in the galectins, which differ
from the cation-dependent site in legume lectins.
A high degree of structural resemblance, and amino-
acid-sequence conservation between CLC protein and
the galectins [9] (at residues which are considered to be
important for carbohydrate binding in the galectins)
suggested that CLC protein might possess a potential
carbohydrate-recognition site. In order to examine the
structural basis for these observations, we superimposed
the CLC protein and galectin-saccharide complex struc-
tures (Fig. 5). The structural alignment (Table 3) high-
lights the details of this site. Indeed, in the CLC protein
structure the conformation of this site is very similar to
that observed in the galectins involving strands S4, S5,
S6a and S6b on the concave face of one 3 sheet. In
galectins -1 and -2 [20-22] this site consists of seven key
residues: His44, Asn46, Arg48, Asn61l, Trp68, Glu71 and
Arg73, and the structurally equivalent residues in the
CLC protein are His53, Gln55, Cys57, Asn65, Trp72,
Gln75 and Glu77 (Figs 3,5). Examination of this site in
these proteins reveals that there is a high degree of struc-
tural conservation on one side of the carbohydrate-binding
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Fig. 5. Superposition of residues in CLC protein and bovine
spleen galectin-1 in the vicinity of the carbohydrate-recognition
site. The residue labels are from the CLC protein structure. The
backbone is shown in cyan. The side chains of CLC protein are
shown as coloured atoms and those of galectin-1 in brown.
N-acetyl-lactosamine (LAC) from the galectin-1 structure is
shown in green. Bound water molecules in the CLC structure at
the carbohydrate-recognition domain are shown as cyan spheres.
(The figure was generated using MOLSCRIPT 74].)
groove with the crucial amino-acid changes Arg48 to
Cys57 and Arg73 to Glu77 occurring on the other side
in the CLC protein (Table 4). Moreover, in galectins -1
and -2 these two arginines are involved in important
hydrogen-bonding interactions with the bound saccha-
ride [20-22]. These arginines are conserved in all known
galectin amino-acid sequences and are responsible for the
tight association with carbohydrate ligands. Thus, there is
an apparent loss of positive charge in the CLC protein
which to some extent is compensated for by the presence
of the Arg61 side chain, that mimics the role played by
the two crucial arginines in the galectins. This arginine
could make a direct hydrogen-bond interaction with
the carbohydrate ligand (Table 4). Two other changes
in the CLC protein structure, Asn46---Gln55 and
Glu71--Gln75, do not appear to cause any major disrup-
tion in possible saccharide-protein interactions. Thus,
there is a 'core binding site' in the CLC protein structure
which could bind potential carbohydrate ligands, and in
our unliganded structure the putative carbohydrate posi-
tion is occupied by five water molecules which are
involved in a network of hydrogen bonds stabilizing the
conformation of this site (Fig. 5).
Carbohydrate-binding activity
In order to determine whether CLC protein possesses
carbohydrate-binding activity, we have performed a
series of experiments using solid-phased saccharides for
affinity chromatography (Figs 6,7). Native CLC protein
in whole cell lysates of AML14.3D10 cells [52], recom-
binant CLC protein in lysates of COS cells transfected
with wild-type or mutant CLC protein expression
vectors [11,53], antibody affinity-purified native CLC
protein, and CLC protein resolubilized from fresh, or
lyophilized and frozen crystals [8], was analysed for its
ability to bind to solid-phased sugars including lactose,
N-acetyl-D-glucosamine, and mannose. Unlike most
galectins, CLC protein did not show strong binding to
any of the solid-phased saccharides tested, regardless of
the source of the protein. In contrast, CLC protein in
lysates of AML14.3D10 cells showed a highly repro-
ducible retarded (delayed) elution on affinity columns of
N-acetyl-D-glucosamine (Fig. 6a), which could be inhib-
ited by inclusion of the free sugar in the cell lysis and col-
umn running buffer (Fig. 6b). This weak binding to
N-acetyl-D-glucosamine was not inhibited by mannose
(Fig. 6c) and CLC protein in cell lysates did not show a
similar weak binding (delayed elution) to solid-phased
mannose (Fig. 6d). CLC protein was also found to have a
weak affinity for lactose, provided the cells were first
lysed in the presence of lactose and then extensively
Table 4. Comparison with CLC of the polar interactions between
galectins and various saccharides.
Sugar Atom Bovine galectin-1 Human galectin-2 CLC
Gal 04 His44 (NE2) 2.8 His45 (Ne2) 2.7 His53 (Ne2) 2.9
Gal 04 Arg48 (NTi2) 3.0 Arg49 (N91) 3.3
Gal 04 Asn46 (N82) 3.4 Asn47 (N82) 3.1 Gin55 (NE2) 2.7
Gal 05 Arg48 (N-T2) 2.9
Gal 06 Asn61 (N82) 2.7 Asn58 (N82) 2.7 Asn65 (N82) 3.4
Gal 06 Glu71 (OE2) 2.8 Glu68 (OE2) 2.6 Gln75 (OE1) 2.9
Nag/Glc 03 Arg73 (Ni2) 3.3 Arg70 (Nq2) 3.1
Nag/Glc 03 Arg48 (Ni11) 2.8 - Arg61 (NI2) 2.9
Nag/Glc 03 Glu71 (OE2) 2.4 Glu68 (OE2) 2.8 Gln75 (OE1 )2.8
Nag/GIc 03 Arg48 (N91 2) 3.2 -
Numbers are the distances in A. Gal, Glc and Nag are the galactose,
the glucose and the N-acetyl-glucosamine moieties, respectively. The
possible CLC polar interactions with N-acetyl-lactosamine which are
shown were deduced after structural superposition of bovine
galectin-1 with CLC protein using the program SHP 172].
Table 3. Superimposition of the potential carbohydrate-
binding site of CLC protein with the carbohydrate-binding site
of the galectins.
rms distance (A)
CLC Galectins* 1 SLT 1 HLCt 1 SLC*
His53 His44 0.93 1.01 1.01
Gln55 Asn46 0.77 0.88 0.71
Cys57 Arg48 0.78 1.31 0.77
Asn65 Asn61 1.06 1.12 1.14
Trp72 Trp68 1.09 0.92 0.72
Gln75 Glu71 0.99 0.71 1.04
Glu77 Arg73 1.28 1.18 1.17
*The numbering refers to bovine spleen galectin-1(1SLT) [30].
Structural alignments have been performed with the program
SHP [72]. *Human galectin-2. *Bovine-heart galectin-1.
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Fig. 6. Low-affinity binding of CLC protein to N-acetyl-D-glu-
cosamine and lactose. CLC protein in lysates of AML14.3D10
cells showed a one to two fraction delay in elution, compared
with the major protein peak, when the lysate was run on an (a)
N-acetyl-o-glucosamine-agarose or (e) lactose-agarose column.
(b) This weak binding could be inhibited by adding 150 mM
N-acetyl-D-glucosamine to the lysis and column running buffer.
(d) The presence of a non-competing sugar (D-mannose) in the
lysis and running buffer did not affect binding (c). CLC did not
bind to D-mannose agarose. (f) Wild-type recombinant CLC (wt-
rCLC) from transiently transfected COS-7 cells showed the same
one fraction delay in elution. (g) Mutation of the Cys29 and
Cys57 residues to Gly (the double mutant) did not block the
weak binding of rCLC to the lactose-agarose column.
dialysed to remove the free sugar and putative endo-
genous oligosaccharide competitors before affinity chro-
matography (Fig. 6e). Hirabayashi and Kasai [23,24] have
utilized a similar chromatographic retardation analysis on
immobilized asialofetuin to assess the carbohydrate-bind-
ing activities of site-specific mutants of human galectin-1
that do not bind strongly to the oligosaccharide ligand.
In addition to the native eosinophil cell line derived pro-
tein, recombinantly expressed wild type CLC protein
(Fig. 6f) showed a similarly weak affinity for the lac-
tose-agarose resin. As mutations at cysteine residues to
block sulphydryl-dependent oxidative inactivation of car-
bohydrate-binding activity have been shown to stabilize
the -galactoside-binding activity of the 14 kDa human
galectin-1 [23], we tested recombinant CLC protein
containing both a Cys29-Gly and Cys57--Gly muta-
tion (Fig. 6g); however, these amino-acid substitutions
neither inhibited nor enhanced the weak affinity of the
recombinant protein for lactose-agarose (Fig. 6g).
Fig. 7. Carbohydrate-binding activity of crystal-derived and affin-
ity-purified CLC protein. Crystallized and resolubilized CLC from
either (a) lyophilized or (b) freshly prepared crystals showed no
binding activity to N-acetyl-D-glucosamine-agarose. Either BSA
or horse myoglobin (1 mg) was mixed with the CLC protein as an
elution marker before loading onto the column. Functionally
active carbohydrate-binding CLC protein could be affinity chro-
matography purified (ACP) using 3.5 M MgCI 2 for elution from
the antibody column (d), but elution at high pH (triethylamine
pH 11.5) completely inactivated the carbohydrate-binding activ-
ity of the purified protein (c), a lability shared by other galectins.
Crystal-derived CLC protein, whether resolubilized
from lyophilized and frozen or from freshly prepared
crystals, did not show any affinity whatsoever for
N-acetyl-D-glucosamine (Fig. 7a,b) or lactose (data not
shown). In this regard, attempts to co-crystallize CLC
protein (resolubilized from fresh or from frozen and
lyophilized CLC crystals) with oligosaccharide ligands
such as lactose, galactose, N-acetyl-D-glucosamine and
mannose have yielded excellent CLC crystals for X-ray
diffraction, but have been uniformly unsuccessful for
demonstrating bound saccharides in the resulting crystal
structures. In contrast, native eosinophil cell line derived
CLC protein, isolated by affinity chromatography on an
anti-CLC protein antibody column, retains its low affin-
ity binding to N-acetyl-D-glucosamine, an activity that
was inactivated when CLC protein was first purified
using alkaline pH elution of the protein from the anti-
body column (Fig. 7c,d). Taken together, these findings
demonstrate low affinity, but specific, binding of CLC
protein to carbohydrate ligands normally bound with
high affinity by most other members of the galectin
superfamily. Moreover, it is evident from the crystal
structure of the CLC protein that it possesses extensive
crystal contacts (Fig. 3a), but these should not compete
with the carbohydrate ligand for space.
Based on the CLC structure, it is possible that the charge
distribution and the absence of the full complement of
Crystal-derived CLC
(from lyophilized crystals)
Crystal-derived CLC
(from fresh crystals)
ACP-CLC eluted with
100rm triethylamine (pH 11.5)
ACP-CLC luted with
3.5 M MgCI (pH 7.1)
Frcio #
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hydrogen-bond interactions (Table 4) may account for the
weak binding of lactose; there is enough room for lactose
to fit into the carbohydrate-binding site by displacing the
cluster of water molecules (Fig. 5). Similarly, the N-acetyl-
D-glucosamine could take the place of the N-acetyl-D-glu-
cosamine moiety of N-acetyl-D-lactosamine. Alternatively,
it might bind in an extended site at the non-reducing side
of galactose [19,22]. This may be a better proposition, as
Arg61 could make a direct hydrogen-bond interaction
in CLC protein with the sugar moiety (or the
non-reducing side of galactose, in which a N-acetyl-D-
glucosamine would be attached at position-3), involving
some conformational rearrangement in the structure.
The location of the lysophospholipase active site
CLC protein directs the expression of LPLase activity and
spontaneous crystallization in transiently transfected COS
cells [11,53]; however, when purified crystals of native or
recombinant CLC protein are resolubilized in Tris buffer
(pH 8.9), the enzyme is essentially inactive (Table 5).
Interestingly, mutation of the Cys57 residue to glycine sta-
bilized the LPLase activity such that the recombinant
mutant retained enzyme activity after crystallization (Table
5). The 3D structure of CLC protein reported here is in
the absence of bound ligand/substrate and does not pro-
vide direct information on the location of the LPLase
active site; however, a potential active site is located (Fig.
8) in a hydrophobic channel topologically situated at one
end of the molecule, some 15 A away from the carbo-
hydrate-recognition domain. Two residues, Tyr100 and
His 14 (located on strands F4 and F5, respectively), point-
ing towards this hydrophobic cavity (the only cavity in the
CLC protein structure as identified using the program
GRASP [54]), appear to be part of this putative active site
and make hydrogen-bond interactions with a bound water
molecule (B factor 14 A2), as shown in Figure 8.
The potential site described here is reminiscent of those
identified in the crystal structures of extracellular phos-
pholipase A2. The most prominent feature of this cat-
alytic site (the catalytic triad), which is formed by a
histidine, an aspartic-acid and a tyrosine residue (e.g.
His47, Asp91 and Tyr51 in human secretory phospholi-
pase A2 [55]), is that it binds to the substrate through
hydrogen-bond interactions. It is known that both histi-
dine and aspartic-acid residues contribute the catalytic
machinery and the tyrosine residue lends structural
support during catalysis, the activation of which is depen-
dent on Ca2+ ions. On the basis of our comparative
analysis, it is tempting to speculate that, in CLC protein,
the bound water molecule might play the role of the
aspartic-acid residue (in phospholipase A2 ). It is thus pos-
sible that in the CLC protein structure, the histidine
residue might be a proton donor, the water molecule may
act like a nucleophile, and the tyrosine residue might be
involved in the catalytic network, thus assisting the bind-
ing of the substrate (i.e. a lysophospholipid); however we
can not rule out the existence of an alternative LPLase
active site, a possibility that requires further investigation.
Discussion
The structural similarity of CLC to galectins -1 and -2 and
sequence similarities to the lectin domain of galectin-3
(the collective term for the 31-35 kDa IgE- and
Fig. 8. A view of the residues in the potential LPLase active site in
the CLC protein structure showing residues Tyr100, His114 and the
water molecule form the potential catalytic triad, as observed in
the native CLC protein structure. Amongst residues Asp98, Aspl 13
and Glu119, one residue may replace the water molecule in the
formation of the catalytic triad in the active form of the structure.
Table 5. Comparative lysophospholipase activity of mutants vs wild type CLC protein before and after crystallization and
resolubilization.
Mutation Mutant 1 Mutant 2 Mutant 3 Wild Type
Codon TGT--GGT TGC--GGC TGT/TGC--GGT/GGC None
Amino acid change Cys29-Gly Cys57-*Gly Cys29/57-Gly None
Lysophospholipase activity*
Before crystallization 3.44 (2.41-4.77) 6.46 (5.19-8.77) 2.45 (2.26-2.62) 1.84 (0.92-2.57)
After crystallization 0.09 (0.05-0.13) 1.91 (0.28-3.82) 0.13 (0.05-0.28) 0.02 (0.0-0.04)
*One unit of lysophospholipase activity represents 1 jlmol of fatty acid released per hour per mg of CLC protein at 370C and pH 7.5.
(Numbers in parentheses indicate the range of values for 3-4 experiments.)
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laminin-binding members of the galectin family) makes
it possible to speculate on its functional role(s) in
eosinophils and basophils. Members of the galectin super-
family have been implicated in cell-matrix interactions
and inflammation (for a review, see [19]). The amino-acid
sequence of CLC protein has similarity to the C-terminal
lectin domain of galectin-3, which includes the major
non-integrin laminin-binding protein of macrophages
(Mac-2), suggesting that CLC protein might be involved
in eosinophil interactions with the polylactosamine
oligosaccharides of extracellular matrix substrates such as
laminin. Galectin-3 binds avidly to laminin [56], shows
differential recognition of certain IgE glycoforms [57]
and induces mast cell histamine secretion by binding the
glycosylated high affinity IgE receptor (FcERI) [41]. In
contrast, the nuclear localization of galectin-3 [58] and its
recent identification as an important factor in pre-
mRNA splicing in the nucleus of HeLa cells [35] empha-
sizes the potential multifunctional nature of many
members of this superfamily. CLC protein has also been
localized, by immunofluorescence and ultrastructural
immunocytochemistry, to two major sites in the
eosinophil: the nucleus and a granule-free space in the
cytoplasm immediately beneath the plasma membrane
[5,11]. This is in addition to its localization in other
minor subcellular compartments, including a minor pop-
ulation of crystalloid-free 'primary' granules [36] and the
cytosol and vesicles of both activated tissue eosinophils
and in vitro differentiated eosinophils derived from IL-5-
induced umbilical cord blood progenitors [34]. In
basophils, CLC protein is present in the large, histamine-
containing granules (as intragranular crystals or crystal-
loids in activated basophils [6]) and in the nucleus [37].
Significant amounts of CLC protein are not secreted dur-
ing receptor-mediated basophil activation, and instead the
protein undergoes a marked cellular rearrangement with
increased nuclear localization [37] (AM Dvorak and SJ
Ackerman, unpublished data). The possibility that CLC
protein could function intracellularly in pre-mRNA
splicing is intriguing and requires further investigation.
Eosinophilic promyelocytes and myelocytes secrete CLC
protein in vitro during eosinophil differentiation and
colony formation in soft agar, possibly by exocytosis of
primary granules [33], and crystals of CLC protein have
been identified in developing eosinophilic promyelocytes
in the bone marrow [7]. Ultrastructural analyses suggest a
process of degranulation/exocytosis of primary granules
in the bone marrow during eosinophil development
(reviewed in [33]) and CLC protein levels are signifi-
cantly elevated in the sinusoidal cavity of the bone mar-
row in normal individuals [33]. Observations that the
expression and localization of the galectins is develop-
mentally regulated suggest that secreted CLC protein in
the bone marrow might play a role in eosinophil or
basophil development, perhaps by functioning extracellu-
larly in the organization of their hematopoietic microen-
vironment. By analogy, externalization of mouse muscle
galectin-1 (L-14) accompanies myoblast differentiation
and this lectin co-distributes with laminin in the myotube
extracellular matrix [29]. Galectin-1 has been shown to
inhibit myoblast adhesion to laminin, suggesting it plays a
role in regulating myoblast detachment from laminin dur-
ing differentiation and fusion into tubular myofibers [59].
Despite no significant sequence or structural similarities
to other lipolytic enzymes including LPLases, phospholi-
pases, and lipases, a possible LPLase catalytic triad has
been identified in the CLC structure, thus making CLC
protein a unique dual function polypeptide. As one of
the most abundant eosinophil constituents, it has been
hypothesized that CLC protein must play a critical role
in eosinophil effector function, either in the pathogenesis
of inflammation and tissue damage in allergic diseases or
in host-parasite interactions. A number of, as yet unsub-
stantiated, hypotheses have been proposed. For example,
the released fatty acid may have membrane perturbing
effects on the eosinophil's target cell. Alternatively, this
LPLase may protect eosinophils from lysophospholipids
and other toxic parasite products. Another possibility is a
direct anti-parasitic effect by hydrolyzing lysophospho-
lipids in the cuticle of parasite targets [60,61]. The fact
that eosinophils (and basophils) contain such large quan-
tities of this enzyme suggests a role for these cells and
CLC protein in the metabolism of lysophosphoglycerides
that may be generated in inflammatory foci by neu-
trophils, in anaphylactic reactions by mast cells, directly
by pathogenic microorganisms, or by helminth parasites
such as schistosomula of Schistosoma mansoni [61].
Schistosomula secrete considerable quantities of mono-
palmitoyl-lysophosphatidylcholine, a potent, biologically
active lysophosphatide that may mediate membrane fusion
and lysis of cytotoxic effector cells by the parasite [62]; as
eosinophils, but not neutrophils, can effectively kill schis-
tosomula in vitro, they may be resistant to the lytic and
membrane-perturbing effects of parasite lysophosphatides
by virtue of their considerable content of this enzyme.
Enzymatically active CLC protein in or on the plasma
membrane could inactivate these lysophosphatides, poten-
tially protecting the eosinophil. An intriguing possibility is
whether schistosomula also express a functional carbohy-
drate ligand for CLC protein that might serve to target
this LPLase to the parasite surface. By altering the stoi-
chiometric balance of phospholipid and free fatty acids
in membranes, CLC protein might act synergistically
to enhance the cytotoxicity or helminthotoxicity of
eosinophil granule cationic proteins such as major basic
protein (MBP) and eosinophil cationic protein (ECP),
both of which have been shown to alter membrane struc-
ture [13,63]. By analogy, bee venom is particularly rich in
both phospholipases (PLA 2) and highly cationic polypep-
tides such as melittin that interact with membranes and
cause cell lysis. The potential for CLC protein's lipolytic
activity to alter membrane fluidity and integrity would
suggest the need for careful intracellular regulation of its
LPLase activity by eosinophils and basophils. The question
of whether endogenous carbohydrate ligands are capable
of regulating the LPLase activity of this dual function
galectin is currently under investigation.
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The biological significance of both the LPLase activity
and crystallization of CLC protein in general remains
unclear. In this regard, the crystallization of CLC protein
enzymatically inactivates both its LPLase activity and
weak carbohydrate binding. A detailed structure-func-
tion analysis, probing the dual activities of CLC protein
using protein engineering experiments, should enable
characterisation of the carbohydrate-recognition domain
and enzymatic active site. It should also provide insight
into the regulatory mechanisms for intracellular and
extracellular expression of LPLase and galectin activities
by these granulocytes, as well as address the unique
propensity and biological role of autocrystallization.
Biological implications
For more than a hundred years, identification of
the distinctive hexagonal bipyramidal crystals of
Charcot-Leyden crystal (CLC) at sites of eosinophil
infiltration in tissues, and in body fluids and secre-
tions, has been a hallmark of eosinophil involve-
ment in allergic, parasitic and inflammatory
disorders. Eosinophils, through secretion of gran-
ule-associated toxic cationic proteins and enzymes,
and lipid mediators, function as proinflammatory
and cytoxic-effector cells in asthma and eosinophil-
associated allergic and parasitic diseases. The CLC
protein comprises -10% of total eosinophil protein
and possesses weak lysophospholipase (LPLase)
activity. Several potential consequences of CLC
protein's LPLase activity in the pathogenesis of
asthma and eosinophil-associated inflammation
have been suggested, but the physiological role of
this enigmatic autocrystallizing protein has
remained highly speculative.
The propensity of CLC protein to crystallize, a
process which inactivates its LPLase activity, is per-
haps the most unique and intriguing of its physico-
chemical properties. Although it has been shown
that crystals of the CLC protein are uniquely
formed by primate but not non-primate
eosinophils, which nevertheless express LPLase
activity, the physiological relevance of this crystal
formation to human eosinophil function is unclear.
The amino-acid sequence of CLC protein shows no
similarities to LPLases, but does share minimal
(20-30%) overall sequence identity with members
of the animal galectin family formerly classified as
S-type or S-Lac (soluble lactose-binding) lectins.
We have determined the three-dimensional struc-
ture of CLC protein at 1.8 A resolution. Its molec-
ular fold is topologically identical to human
galectins -1 and -2, members of the aforemen-
tioned galectin family. The structure reveals a car-
bohydrate-recognition domain with most of the
carbohydrate-binding residues conserved among
the galectins. From detailed structural comparisons
of CLC protein with galectins and other 'jelly-roll'
proteins, it is evident that the stable core -sand-
wich motif has been conserved during evolution;
however, each of these lectins have different func-
tions and carbohydrate-ligand specificities, reflect-
ing multiple modes of carbohydrate binding.
Although CLC protein shows specific (albeit weak)
affinity for simple saccharides such as N-acetyl-D-
glucosamine and lactose, a biologically relevant
carbohydrate ligand remains to be identified.
Galectins may function in cell-cell and cell-matrix
interactions in development and inflammation.
Both CLC protein and galectin-3 have been pro-
posed to be involved in allergic responses.
Galectin-3, the major non-integrin laminin and
IgE-binding protein of macrophages (also known
as Mac-2), is expressed in eosinophils, neutrophils
and epithelial cells. Galectin-3 can activate mast
cell mediator release through binding to the high-
affinity IgE receptor. Intracellularly, galectin-3
functions as a nuclear factor in pre-mRNA splic-
ing. Considering CLC protein's cellular content,
cytosolic and nuclear localization, and the poten-
tial multifunctional nature of many members of
the galectin superfamily, our structural and func-
tional findings suggest that it will possess galectin-
associated activities that may be extremely
important to eosinophil development, function
and inflammatory activities, both in allergic dis-
eases and host-parasite interactions.
Materials and methods
Preparation of affinity-purified and crystal-derived CLC
protein
Rabbit anti-CLC antibodies were affinity purified, as described
previously [6,36], using a solid-phase CLC-Sepharose column.
Antibodies were bound directly to protein A-Sepharose (Phar-
macia, Piscataway, NJ) and chemically cross-linked using
dimethylpimelimidate. CLC protein was affinity purified from
AML14.3D10 cell lysates using the anti-CLC protein column.
100 mM triethylamine or 3.5 M MgC1 in PBS pH 7.1 was
used to elute CLC protein bound to the antibody affinity col-
umn. Following elution, the CLC protein was dialysed for
24 h against pH 7.1 PBS and concentrated 10-50 fold using a
stirred ultrafiltration cell (Amicon, Beverly, MA) equipped
with a YM10 membrane (Amicon). Purity of the affinity-
isolated CLC protein was assessed by silver-stained SDS-PAGE
gels. CLC crystals were made as previously described [8]. CLC
protein from either freshly prepared, or lyophilized and frozen
CLC, was resolubilized in PBS pH 7.4 by stirring at room tem-
perature for 3 h. Solutions of CLC protein containing approxi-
mately 150-300 g ml-1 were obtained using this method.
Crystallization
Details of the crystallization of CLC protein during preliminary
X-ray diffraction analysis have been described elsewhere [64].
Purified crystal-derived CLC protein was recrystallized using
the hanging drop vapour diffusion method. Drops containing
protein (5 mg ml-1) at pH 10.5 in 0.1 M Tris were equilibrated
against reservoirs of 0.2 M Tris-acetate buffer (pH 7.0). Hex-
agonal bipyramidal crystals (approx. 2.0x0.25x0.25 mm) were
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grown after 3-4 days at 16°C; these crystals possess the same
morphology as those found in vivo. CLC protein crystals dif-
fract to minimum Bragg spacings of 1.8 A using a synchrotron
radiation source. The systematic absences and symmetry were
consistent with space group P6 122 or P6522 (later confirmed to
be P6522) with unit cell dimensions of a=b=49.6 A,
c=262.2 A. There is one molecule of CLC protein per crystal-
lographic asymmetric unit and approximately 52% of the crys-
tal volume is occupied by solvent.
Diffraction measurements
Diffraction data were collected on stations PX 9.5 (derivatives)
and PX 9.6 (native) of the Synchrotron Radiation Source,
Daresbury, UK, using a 30 cm diameter MAR-research image
plate. Native data to 1.8 A resolution were collected from two
crystals at 16°C. A 0.2 mm collimator was used. A typical
exposure time was 120 s for 0.5 ° oscillation. The crystal to
image plate distance was kept at 287 mm during data collection
for the native crystals.
Heavy atom derivatives obtained using p-chloromercuriben-
zenesulfonic acid (p-CMBS) (SIGMA), and potassium tetra-
chloro platinate ( KPtCI4) (SIGMA) were used to determine
the CLC structure. The native crystals were soaked for 22 h in
solutions of the mother liquor containing 10 mM of KPtCl4
while the crystals were equilibrated in 3% PEG 4000 to pre-
vent the dissolution of the crystal prior to the soaking experi-
ments. Crystals cocrystallized with 2 mM p-CMBS were also
used. Data were collected to 3.4 A resolution with an X-ray
beam (0.2 mm collimator) of wavelength 0.92 A. One crystal
per data set was used (at 16°C) with an oscillation range of 1.5°
per image. The exposure time was 90 s and the crystal to image
plate distance was set at 325 mm.
The bipyramidal crystals were generally mounted with the long
axis of the crystal lying parallel to the capillary axis, but were
generally offset by a few degrees relative to the oscillation axis
to achieve a more efficient coverage of measured reflections.
For the native crystals, 50 ° of data were collected to minimize
the 'missing cone'of data.
Raw data images were indexed, integrated and data reduction
were performed using the program DENZO [65]. The details
of data processing statistics for the three datasets used in the
structure determination are presented in Table 1.
Phasing
The structure of CLC protein was determined by the method
of multiple isomorphous replacement (MIR). Scaling of native
and derivative data, Patterson map calculations, heavy-atom
refinement, solvent flattening, combination of model and MIR
phases, along with electron-density map calculations, were per-
formed using the programs available in the PHASES package
[66]. The initial MIR phases were calculated using reflections
with F/arF>2.0 to a resolution limit of 3.4 A. For the conven-
tional heavy-atom parameter refinement only reflections with
phases with figure of merit (FOM) better than 0.60 were used
(Table 1). During refinement of these parameters of one deriv-
ative the contribution from both derivatives to the phasing was
used. The final FOM was 0.60 for 3014 phased reflections
between 15 and 3.4 A. The protein phases were improved by
solvent flattening the electron-density map [67] (solvent con-
tent 52%), using the protocol implemented in the PHASES
package and further heavy-atom refinement against the protein
phases calculated from the solvent-flattened MIR electron-
density map.
Map interpretation
Electron-density maps were displayed and model coordinates
were fitted on an Indigo 2 Silicon Graphics workstation using
the interactive computer graphics program 0, version 5.10.2
[68]. First, Coet atoms were assigned to the skeleton positions
and then a polyalanine model was built by performing a data-
base search to obtain the best-fitting peptide with respect to
the Cot position. Using the amino-acid sequence of CLC pro-
tein [9] two models, containing 138 residues with all the side
chains, were built (at 3.4 A), one for each enantiomer (P6 122
and P6 522).
Refinement
All refinement was carried out using the program X-PLOR
[69]. In order to resolve the ambiguity regarding the space
group assignment for CLC crystals, refinement was performed
using molecular dynamics and energy minimization for the two
enantiomers. After one round of refinement, for the model in
space group P6122, the crystallographic R factor (Rryst) con-
verged to 33.5% but the Rfree, calculated with 5% of data which
was omitted from the refinement, was 57.4%. In contrast, the
model in space group P6522 had an Rcrst value of 28.4% and
the Rfree was 48.3%, using the same dataset as in space group
P6 122, indicating P6s22 was the correct space group. Further
calculations were carried out in this space group.
Calculated phases obtained from the refined structure were
combined with the original (that is, not the solvent flattened)
MIR phases and used to determine a new electron-density map.
Careful examination of the maps allowed corrections to be
incorporated into the model. Alternating cycles of manual
building, conventional positional refinement and simulated
annealing method, as implemented in X-PLOR, improved the
model. Rebuilding was initially performed at 3.4 A resolution,
using electron-density maps calculated from combined
model/MIR phases. Extension of refinement from 3.4 A to
1.8 A resolution was performed in 0.1 A resolution steps and
the quality of the model was monitored using 2 1 Fo I - I Fc (calc
maps. The behaviour of the Rfree value was also monitored all
through refinement. After several rounds of refinement, model
building and individual B-factor refinement (using all data from
8-1.8 A resolution, 17687 reflections) gave a final model with
crst of 20.0% and last recorded R free of 25.8% for a randomly
selected 5% subset of reflections not used in the refinement
[69]. Rms deviations from ideality of bond lengths and bond
angles were 0.010 A and 1.61 °, respectively. During the final
stages of refinement, water molecules were inserted into the
model only if there were peaks in the I F I - I Fc I electron-
density maps with heights greater than 3 and they were at
hydro en-bond forming distances from appropriate atoms.
2|Fo | -Fc |I calc maps were also used to check the consistency
in peaks. Water molecules with a temperature factor higher
than 60 A2 were excluded from subsequent refinement steps. A
portion of the 2 F I - Fc | calc final electron-density map (at
1.8 A resolution), contoured at 1.0r, is shown in Figure 1.
Validation of the model
The final refined model at 1.8 A resolution comprised 141
residues (1145 protein atoms) and 77 water molecules. The
program PROCHECK [70] was used to assess the quality of
the final structure. Analysis of the Ramachandran (p-t)
plot showed that all residues lie in the allowed regions
except Arg128 which is in a generously allowed region.
Secondary structural alignments and solvent accessibilities were
calculated utilising the DSSP program [71]. Structural super-
positions were performed using the program SHP [72]. Atomic
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coordinates for structural comparisons were obtained from the
Brookhaven Protein Data Bank.
Cell culture, plasmids and transfections
AML14.3D10 is a fully differentiated eosinophilic myelocyte
subline of the AML14 and AML14. eos cell lines [52] that con-
tinues to proliferate and maintain a differentiated phenotype
without cytokine supplementation. AML14.3D10 cells were
maintained in RPMI 1640 medium supplemented with
L-glutamine (2 mM), 2-mercaptoethanol (0.05 mM), sodium
pyruvate (1 mM) and 8% fetal bovine serum (GIBCO,
Gaithersburg, MD). COS-7 cells were obtained from the
American Type Culture Collection. COS-7 cells were main-
tained as monolayers at 37°C in a 5% CO, atmosphere in Dul-
becco's modification of Eagle's medium (Mediatech, Herndon,
VA) supplemented with L-glutamine (2 mM), penicillin
(100 U ml-'), streptomycin (0.1 mg ml-') and 10% fetal bovine
serum (HyClone, Logan, UT). Site-directed mutagenesis of
Cys29--Gly (TGT--4GGT) and Cys57-->Gly (TGC---GGC)
was accomplished using primer 1 (5'-GCCTgaattcGGGCAA-
TTC-3'), containing an EcoRI cutting site (indicated in lower
case letters), primer 2 (5'-CACctgcagATATGGTTCATTCA-
AGAAACCGAC-3', antisense), containing a Pstl site and a
mismatched base (underlined) used to mutagenize Cys29, and
primer 3 (5'GTtcatgaCCACACGACGACCAAAGCCCAC-
3'), containing a mismatched base (used to mutagenize Cys57)
and a BspH 1 site. Primers and 2 were designed to create a
PCR fragment containing the Cys29--Gly mutation and
primers and 3 were used to create a PCR fragment contain-
ing the Cys 57-*Gly mutation. These PCR fragments, used to
substitute for the corresponding segments in the wild-type
CLC cDNA, were ligated into an EcoRI-digested, phos-
phatase-treated pMT2 eukaryotic expression vector [73] to
create the desired mutant constructs [53]. The double mutation
(Cys29--Gly and Cys57-Gly), derived from a combination of
the Cys29 and Cys57 mutants, was created by substitution of
the Cys29-4Gly mutant PCR fragment at the corresponding
position in the Cys57-4Gly mutant. Both mutations were con-
finnrmed by DNA sequencing of the PCR generated constructs.
The wild type CLC cDNA and the Cys29/Cys57--Gly
mutant cDNA in the pMT2 expression vector were transfected
into COS-7 cells using the DEAE dextran technique as
previously described for the production of recombinant CLC
protein [11]. After 72 h, cells were harvested and lysed in
pH 7.4 PBS, containing 1% NP-40, centrifuged at 3 5000g for
20 min, and the supernatant was applied immediately to the
glycoconjugate affinity columns. AML14.3D10 cells were lysed
under the same conditions.
Assessment of carbohydrate-binding activity
The carbohydrate-binding activity of native or recombinant
CLC protein was determined as a delay in the elution [24] of
CLC protein (measured by RIA in lg ml- l, range 0.01-100
lg ml-', as described previously [8]), compared with the major
protein peak (measured as absorbance at 280 nm, range 0-15
units). The bed volume of the N-acetyl-D-glucosamine-
agarose (SIGMA, St Louis, MO), lactose-agarose (SIGMA)
and D-mannose-agarose (SIGMA) columns was 5 ml. Flow
rate was 6 nml h-'. After loading the sample, the columns were
washed with pH 7.4 PBS running buffer in the absence or
presence of competing sugar until the A,) returned to a zero
baseline. All columns were then eluted with 150 mM compet-
ing sugar. In the case of pure CLC protein, I mg of bovine
serum albumin or horse myoglobin was mixed with the CLC
protein prior to loading on the column to provide a protein
marker detectable- at A280.
Lysophospholipase activity assay
The effects of the Cys to Gly mutations on LPLase activity
were determined using transiendtly transfected COS cells as pre-
viously described [11,53]. COS cells were collected by cell
scraping at 72 h after transfection and washed with PBS. The
cells were sonicated (4 x15 s sonication bursts with min
intervals for cooling) on ice using a Model 450 sonifier
(Branson Ultrasonic Corp., Danbury, CT) with a microtip at a
constant duty cycle and power setting of 3.5. The crude soni-
cates were centrifuged at 10000 g at 4C for 20 min and the
supernatant was used for measurement of LPLase activity
[11,12]. One unit of LPLase activity represents 1 pimol of
released fatty acid h -1 mg-1 CLC protein (as measured by
RIA) at 37C and pH 7.5. In addition, the mutant and wild-
type recombinant (wt-rCLC) proteins were also used for
determination of LPLase activity after crystallization and resol-
ubilization. The concentrations of the resolubilized crystal-
derived mutants and wild type rCLC protein were measured
by either RIA [8] or Bradford protein assay as described by the
manufacturer (Bio-Rad, Richmond, CA).
Atomic coordinates for human CLC protein are being
deposited with the Brookhaven Protein Data Bank.
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